Chongqing Pharscin Pharmaceutical (002907.SZ): Becomes the marketing authorization holder of Clopidogrel Bisulfate Tablets.

Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company completed the change of the "Pharmaceutical Production License" for Clopidogrel Bisulfate Tablets in July 2026, and recently received the "Drug Supplementary Application Approval Notice" for the product approved and issued by the National Medical Products Administration, marking that the product has completed the change of the drug marketing authorization holder, and the company has become its drug marketing authorization holder. It is reported that Clopidogrel Bisulfate Tablets are commonly used antiplatelet aggregation drugs in clinical practice, belonging to the national medical insurance (Category B) drugs and national essential drugs. Clinically, they are mainly used for the prevention and treatment of heart, brain and other arterial circulation disorders caused by high platelet aggregation, such as recent-onset stroke, myocardial infarction and confirmed peripheral arterial disease.